CareDx, Inc., a leading innovator in the field of transplant diagnostics, is headquartered in the United States. Founded in 1998, the company has established itself as a key player in the biotechnology industry, focusing on improving the lives of transplant patients through advanced genomic solutions. With a strong presence in major operational regions across North America and Europe, CareDx offers unique products and services, including AlloSure and AlloMap, which provide non-invasive monitoring of organ transplant health. These offerings are distinguished by their ability to deliver precise, actionable insights that enhance patient care and outcomes. Recognised for its commitment to innovation, CareDx has achieved significant milestones, positioning itself as a trusted partner in transplant medicine. The company continues to lead the market with its cutting-edge technologies, contributing to the evolving landscape of personalised healthcare.
How does CareDx, Inc's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
CareDx, Inc's score of 25 is lower than 60% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, CareDx, Inc. reported total carbon emissions of approximately 525,000 kg CO2e from Scope 1 and 2 combined. This figure includes significant emissions from their operations in the US, where Scope 2 emissions alone accounted for about 456,000 kg CO2e. Additionally, the company reported Scope 2 emissions of approximately 54,000 kg CO2e in Australia and 15,000 kg CO2e in Sweden. In 2023, CareDx's global emissions for Scope 1 and 2 were approximately 1,138,000 kg CO2e, with the US contributing about 1,048,000 kg CO2e from Scope 2 emissions, and Australia reporting around 83,000 kg CO2e from the same scope. Sweden's Scope 2 emissions for that year were about 7,000 kg CO2e. Despite these figures, CareDx has not set specific reduction targets or initiatives, as indicated by the absence of documented reduction targets or commitments to frameworks such as the Science Based Targets initiative (SBTi). The company does not appear to inherit emissions data from a parent organisation, maintaining a standalone approach to its climate commitments. Overall, CareDx's emissions data reflects a significant operational footprint, particularly in the US, with ongoing opportunities for improvement in their climate strategy.
Access structured emissions data, company-specific emission factors, and source documents
| 2023 | 2024 | |
|---|---|---|
| Scope 1 | - | - |
| Scope 2 | - | - |
| Scope 3 | - | - |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
CareDx, Inc is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
